124 related articles for article (PubMed ID: 15624648)
1. [Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Paukstadt W
MMW Fortschr Med; 2004 Nov; 146(47):12, 14. PubMed ID: 15624648
[No Abstract] [Full Text] [Related]
2. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
4. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
5. Nothing succeeds like failure.
Nat Biotechnol; 2002 Feb; 20(2):101. PubMed ID: 11821837
[No Abstract] [Full Text] [Related]
6. Two new drugs for colon cancer.
Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
[No Abstract] [Full Text] [Related]
7. Targeting vascular endothelial growth factor in colorectal cancer.
Berlin JD
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
[TBL] [Abstract][Full Text] [Related]
8. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
[TBL] [Abstract][Full Text] [Related]
9. New response criteria proposed for immunotherapies.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(18):1280-1. PubMed ID: 18780859
[No Abstract] [Full Text] [Related]
10. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
Miller KD
Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
[No Abstract] [Full Text] [Related]
11. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
13. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
14. Potential role of inhibiting the vascular endothelial growth factor pathway in advanced prostate cancer.
Clin Prostate Cancer; 2005 Sep; 4(2):80-2. PubMed ID: 16197606
[No Abstract] [Full Text] [Related]
15. Monoclonal antibody therapies shine in breast cancer clinical trials.
Hampton T
JAMA; 2005 Jun; 293(24):2985-9. PubMed ID: 15972551
[No Abstract] [Full Text] [Related]
16. [Anti-cancer monoclonal antibody].
Sasaki S; Ishida T; Tsujisaki M; Imai K
Nihon Rinsho; 2005 Apr; 63 Suppl 4():608-12. PubMed ID: 15861718
[No Abstract] [Full Text] [Related]
17. New drugs for ovarian cancer.
Kaye SB
Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
[No Abstract] [Full Text] [Related]
18. [Cancerology: search for better therapeutic schemes].
Mabro M
Presse Med; 1998 Jul 4-11; 27(24):1228-30. PubMed ID: 9767784
[No Abstract] [Full Text] [Related]
19. Highlights from the 2019 San Antonio Breast Cancer Symposium.
Rugo HS
Clin Adv Hematol Oncol; 2020 Mar; 18(3):157-159. PubMed ID: 32609664
[No Abstract] [Full Text] [Related]
20. The role of targeted therapy in the treatment of colorectal cancer.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
